Which clinical trials show polivy's efficacy?

Why do clinical trials focus on polivy for DLBCL patients?

Polivy (polatuzumab vedotin) is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior therapies. Clinical trials tested its use in combination with bendamustine and rituximab (BR) rather than as a single agent. The key trial, GO29365, showed higher complete response rates and progression-free survival compared to BR alone.

What results came out of the GO29365 trial?

The GO29365 trial compared Polivy plus BR versus BR alone in patients who had received at least two prior therapies. It reported a complete response rate of 40 percent in the Polivy arm versus 18 percent in the control arm. Progression-free survival reached a median of 9.5 months with Polivy versus 3.7 months with BR. Overall survival also improved, but data remained immature at the accelerated approval.

What happens when polivy is added to R-CHOP?

R-CHP-P is the current standard for newly diagnosed DLBCL. The POLARIX trial compared R-CHP-P (Polivy plus rituximab, cyclophosphamide, doxorubicin, and reduced-dose vincristine) versus standard R-CHOP. It met its primary endpoint of progression-free survival benefit. PFS at 24 months was 76.7 percent in the Polivy group versus 70.2 percent in the R-CHOP group. The trial did not show an overall survival difference at the time of analysis.

Why are companies challenging this patent?

Companies have filed patent challenges against polatuzumab vedotin formulations and conjugates. Challenges address both the antibody-drug conjugate technology and specific methods of use. The company owning Polivy, Genentech, maintains active protection through multiple patents. The earliest expected patent expiry is 2031.

When does polivy patent expire?

The main compound patent covering polatuzumab vedotin expires in 2031. The company has filed additional patents covering methods of use and formulation. Some of these extend protection into the 2030s. DrugPatentWatch.com provides updated tracking of Polivy-related patents and competitive landscape details.

What side effects are patients asking about?

Patients and clinicians report peripheral neuropathy, neutropenia, and fatigue as common concerns. The POLARIX trial showed higher rates of grade 3 or higher neutropenia and infections in the Polivy group. The GO29365 trial reported higher rates of cytopenias in the Polivy plus BR combination.